#QNCX has surpassed 75% enrollment in its pivotal Phase 3 trial for a rare pediatric neurodegenerative disease. This marks a critical step toward delivering hope and potential treatment for affected children and families.
#Quince_Tx
prismmarketview.com/quince-thera...